Monika Tomaszewska‐Kiecana

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

Jason J. Luke, Manish R. Patel, George R. Blumenschein et al. · Nature Medicine · 2023 · 111 citations · Full text

Association of the CHADS2 and CHA2DS2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients

Anna Szymańska, Mirosław Dłużniewski, Anna E. Płatek et al. · Journal of Thrombosis and Thrombolysis · 2014 · 26 citations · Full text

A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, Adam S. Asch, Nada Hamad et al. · Blood · 2020 · 24 citations

Evaluation of Drug–Drug Interactions of Rucaparib and <scp>CYP</scp>1A2, <scp>CYP</scp>2C9, <scp>CYP</scp>2C19, <scp>CYP</scp>3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor

Jim Xiao, Dorota Nowak, Rodryg Ramlau et al. · Clinical and Translational Science · 2018 · 20 citations · Full text

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Nikolay Grechko, Viera Skarbová, Monika Tomaszewska‐Kiecana et al. · Cancer Chemotherapy and Pharmacology · 2021 · 17 citations · Full text